Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 123-129

  Bakker Arkema, Rebecca G ^a   Nawrocki, James W ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

Author keywords

Hypercholesterolemia; LDL C; Low cholesterol; Safety; Statins

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FLATULENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0033999484     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00294-4     Document Type: Article

References (23)

1. Castelli W.P., Anderson K., Wilson P.W. et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 2:1992;23-28.
2. LaRosa J.C., Hunninghake D., Bush D. et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 81:1990;1721-1733.
3. Verschuren W.M., Jacobs D.R., Bloemberg B.P. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. J. Am. Med. Assoc. 274:1995;131-136.
4. Castelli W.P., Garrison R.J., Wilson P.W.F. et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J. Am. Med. Assoc. 256:1986;2835-2838.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
7. Sacks FM, Pfeffer MA, Moyé LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349-1357.
9. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615-1622.
10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015-3023.
11. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503.
12. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
13. LaRosa JC for the TNT Steering Committee. Effect of lowering LDL-C beyond currently recommended minimum targets - the treating to new targets (TNT) study. Presented at the XIIIth International Symposium on Drugs Affecting Lipid Metabolism, May 30-June 3 1998, Florence, Italy.
14. Nawrocki J.W., Weiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15(5):1995;678-682.
15. Black D.M., Bakker-Arkema R.G., Nawrocki J.W. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. 158:1998;577-584.
16. Best J.D., Nicholson G.C., O'Neal D.N. et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab. Nutr. Metab. 9:1996;74-80.
17. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms, 4th edition. Washington, DC: Food and Drug Administration, Department of Health and Human Services, 1993.
18. Pitt B, Waters D, Brown WV et al. for the AVERT Investigators. Effects of lipid lowering with atorvastatin on cardiovascular ischemic events: results of the atorvastatin versus revascularization treatments (AVERT) study. N Engl J Med 1999;341:70-6.
19. Jones P, Kafonek S, Laurora I et al for the CURVES investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587.
20. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br. Med. J. 301:1990;309-314.
21. Smith G.D., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br. Med. J. 304:1992;431-434.
22. Oliver M.F. Doubts about preventing coronary heart disease. Br. Med. J. 304:1992;393-394.
23. Jacobs D.R., Blackburn H., Higgins M. et al. Report of the conference on low blood cholesterol: mortality associations. Circulation. 86:1992;1046-1060.